Premium
Prognostic Value of Ki‐67, CD31 and Epidermal Growth Factor Receptor Expression in Basal Cell Carcinoma
Author(s) -
Yerebakan Özlem,
Çiftçiog͂lu Mehmet Akif,
Akkaya Bahar Kiliçarslan,
Yilmaz Ertan
Publication year - 2003
Publication title -
the journal of dermatology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.9
H-Index - 65
eISSN - 1346-8138
pISSN - 0385-2407
DOI - 10.1111/j.1346-8138.2003.tb00330.x
Subject(s) - cd31 , epidermal growth factor receptor , immunohistochemistry , basal cell carcinoma , basal (medicine) , pathology , epidermal growth factor , biology , cell , receptor , cancer research , medicine , basal cell , insulin , genetics
Recurrence of basal cell carcinoma following treatment is common, and the majority of recurrences appear in the first 3 years. We examined the original tumors of 26 basal cell carcinoma cases, 14 of whom had a recurrence after an average of 3.7 years, and 12 of whom had no recurrence during an average of 4.4 years follow‐up. Using immunohistochemistry, we tested for Ki‐67, CD31 and epidermal growth factor receptor expressions in the tumor tissue. The percentages of expression for Ki‐67, CD31 and epidermal growth factor receptor were significantly higher in the recurrent tumors than in the non‐recurrent ones. Expression of Ki‐67 and CD31 was 271.57 ± 17.91 and 58.1 ± 9.37 for the recurrent group and 187.08 ± 21.48 and 23.9 ± 5.45 for non‐recurrent group respectively (p<0.0001; p<0.0001). Expression of epidermal growth factor receptor was positive in all basal cell carcinoma cells. The staining intensity was strong in 57% of recurrent and 8.3% of non‐recurrent tumors (p=0.014). These results show that Ki‐67, CD31 and epidermal growth factor receptor expression differ between basal cell carcinomas which later recur and those that do not recur.